EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
Accounts Payable
EyePoint Pharmaceuticals Inc
Accounts Payable Peer Comparison
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Accounts Payable
$7.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
2%
|
CAGR 10-Years
24%
|
|
Johnson & Johnson
NYSE:JNJ
|
Accounts Payable
$8.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accounts Payable
$3.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
12%
|
CAGR 10-Years
4%
|
|
Pfizer Inc
NYSE:PFE
|
Accounts Payable
$5.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
Merck & Co Inc
NYSE:MRK
|
Accounts Payable
$3.5B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Eli Lilly and Co
NYSE:LLY
|
Accounts Payable
$2.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
16%
|
CAGR 10-Years
8%
|
See Also
What is EyePoint Pharmaceuticals Inc's Accounts Payable?
Accounts Payable
7.1m
USD
Based on the financial report for Mar 31, 2024, EyePoint Pharmaceuticals Inc's Accounts Payable amounts to 7.1m USD.
What is EyePoint Pharmaceuticals Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
24%
Over the last year, the Accounts Payable growth was -25%. The average annual Accounts Payable growth rates for EyePoint Pharmaceuticals Inc have been 6% over the past three years , 2% over the past five years , and 24% over the past ten years .